A comparative pharmacokinetic study of PARP inhibitors demonstrates favorable properties for niraparib efficacy in preclinical tumor models

Niraparib is an orally bioavailable and selective poly (ADP-ribose) polymerase (PARP)-1/-2 inhibitor approved for maintenance treatment of both BRCA mutant (mut) and BRCA wildtype (wt) adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancers who have demonstrat...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncotarget
Main Authors: Sun, Kaiming, Mikule, Keith, Wang, Zebin, Poon, Grace, Vaidyanathan, Aparajitha, Smith, Gillian, Zhang, Zhi-Yi, Hanke, Jeffrey, Ramaswamy, Sridhar, Wang, Jing
Formato: Artigo
Idioma:Inglês
Publicado em: Impact Journals LLC 2018
Assuntos:
Research Paper
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6324689/
https://ncbi.nlm.nih.gov/pubmed/30647846
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.26354
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados